Select Vaccines partner ships hep E kits to hotspot
Wednesday, 08 September, 2004
Select Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
The kits, which were provided to the WHO on a humanitarian basis, will be used in the Darfur region of Sudan to help contain an outbreak of hepatitis E in the refugee camps. Select Vaccines licensed the hepatitis E rapid diagnostic kit, as well as a laboratory diagnostic to Genelabs for a 12-year term in August, in return for upfront payments and royalties.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
